"RIV/00216208:11150/06:00004326" . "[CB68737AC5B9]" . . "Rezistence na protidesti\u010Dkovou terapii v kardiologick\u00E9 praxi"@cs . . "Rezistence na protidesti\u010Dkovou terapii v kardiologick\u00E9 praxi" . "4"^^ . "Rezistence na protidesti\u010Dkovou terapii v kardiologick\u00E9 praxi"@cs . "Interven\u010Dn\u00ED a akutn\u00ED kardiologie" . "Resistance to antiplatelet therapy in clinical cardiology"@en . "6" . . "5" . . . "Nov\u00FDm patofyziologick\u00FDm fenom\u00E9nem s mo\u017En\u00FDm klinick\u00FDm dopadem je rezistence na protidesti\u010Dkovou terapii. Definovat ji m\u016F\u017Eeme klinicky i laboratorn\u011B. Etiologie je komplexn\u00ED, z\u00E1visl\u00E1 na genetick\u00FDch, bun\u011B\u010Dn\u00FDch a klinick\u00FDch faktorech. Prevalence ASA rezistence je 5-45% v z\u00E1vislosti na pou\u017Eit\u00E9 metodice." . "Resistance to antiplatelet therapy in clinical cardiology"@en . . "Mal\u00FD, Jaroslav" . "Pecka, Miroslav" . "256;258" . "Rezistence na protidesti\u010Dkovou terapii v kardiologick\u00E9 praxi" . "Resistance to antiplatelet therapy is the recent phenomenom with potential clinical influence. We can define resistance to antiplatelet therapy clinically or laboratory. Etiology of resistance to antiplatelet therapy is complex. The percentage of ASA non-responders fluctuates from 5 to 45% depending on the methods used."@en . . "CZ - \u010Cesk\u00E1 republika" . . . "11150" . "3"^^ . "acetylsalicyclic acid; ischaemic heart disease; clopidogrel; ASA resistance; aggregometry"@en . . "1213-807X" . "Z(MSM0021620817), Z(MZ0FNHK2005)" . . "RIV/00216208:11150/06:00004326!RIV07-MSM-11150___" . . . "Voj\u00E1\u010Dek, Jan" . . . "Pudil, Radek" . . "6"^^ . . "497543" . "Nov\u00FDm patofyziologick\u00FDm fenom\u00E9nem s mo\u017En\u00FDm klinick\u00FDm dopadem je rezistence na protidesti\u010Dkovou terapii. Definovat ji m\u016F\u017Eeme klinicky i laboratorn\u011B. Etiologie je komplexn\u00ED, z\u00E1visl\u00E1 na genetick\u00FDch, bun\u011B\u010Dn\u00FDch a klinick\u00FDch faktorech. Prevalence ASA rezistence je 5-45% v z\u00E1vislosti na pou\u017Eit\u00E9 metodice."@cs . . . . .